Dlin-MC3-DMA: Ionizable Cationic Liposome for mRNA & siRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is a potent ionizable cationic liposome lipid used in lipid nanoparticle (LNP) siRNA and mRNA delivery systems. It enables efficient endosomal escape and cytoplasmic delivery due to its pH-sensitive charge profile, remaining neutral at physiological pH and positively charged in acidic endosomes [1]. In animal models, Dlin-MC3-DMA achieves up to 1000-fold greater potency in hepatic gene silencing compared to its precursor DLin-DMA [2]. The lipid is insoluble in water and DMSO but soluble in ethanol at concentrations ≥152.6 mg/mL, and must be stored at -20°C or below [2]. LNPs formulated with Dlin-MC3-DMA show superior in vivo delivery of siRNA and mRNA, validated by both machine learning models and animal studies [1]. APExBIO supplies Dlin-MC3-DMA (SKU: A8791) as a research-grade standard for advanced LNP formulations.

Biological Rationale

Messenger RNA (mRNA) and small interfering RNA (siRNA) therapeutics require stable, efficient delivery systems to achieve intracellular function. Naked RNA molecules are rapidly degraded by nucleases and poorly internalized by cells [1]. Lipid nanoparticles (LNPs) encapsulate and protect nucleic acids, facilitating cellular uptake and endosomal escape. Ionizable cationic lipids, such as Dlin-MC3-DMA, are foundational components of LNPs. Their pH-sensitive charge allows for efficient binding and release of nucleic acids, as well as reduced toxicity in systemic circulation [3]. This approach enables applications in hepatic gene silencing, cancer immunochemotherapy, and mRNA vaccine development.

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA is an ionizable amino lipid with a tertiary amine head group. At physiological pH (7.4), the molecule is predominantly neutral, minimizing nonspecific interactions and toxicity. Upon endocytosis, the acidic endosomal environment (pH ~5.5) protonates the amine, rendering the lipid positively charged. This facilitates electrostatic interaction with anionic endosomal membrane lipids, destabilizing the membrane and promoting endosomal escape of encapsulated RNA [1]. This mechanism is a critical determinant of high-efficiency cytoplasmic delivery and gene silencing. Compared to earlier lipids such as DLin-DMA, Dlin-MC3-DMA exhibits increased potency due to improved pKa and membrane-disruptive properties [2]. LNPs typically include Dlin-MC3-DMA, DSPC, cholesterol, and PEG-DMG to optimize stability and delivery efficiency [4].

Evidence & Benchmarks

• Dlin-MC3-DMA-containing LNPs achieved higher mRNA delivery efficiency in mice than those using SM-102, confirmed by IgG titer and in vivo imaging (Wang et al. 2022, DOI).
• Dlin-MC3-DMA demonstrated an ED₅₀ of 0.005 mg/kg for hepatic factor VII gene silencing in mice, 1000-fold more potent than DLin-DMA (APExBIO product data, source).
• Machine learning models (LightGBM) identified Dlin-MC3-DMA's substructures as optimal for LNP-based mRNA vaccine efficacy, with R² > 0.87 for experimental prediction (Wang et al. 2022, DOI).
• In non-human primates, Dlin-MC3-DMA LNPs silenced transthyretin (TTR) gene expression with ED₅₀ = 0.03 mg/kg (APExBIO, source).
• Dlin-MC3-DMA is insoluble in water or DMSO but soluble in ethanol at ≥152.6 mg/mL, enabling high-concentration stock solutions for LNP assembly (APExBIO, source).

Applications, Limits & Misconceptions

Dlin-MC3-DMA is the gold standard ionizable cationic lipid for nucleic acid delivery in LNPs, especially in hepatic gene silencing, mRNA vaccine formulation, and cancer immunochemotherapy [5]. This article extends previous discussions by providing detailed benchmarks and molecular design rationale. Its pH-responsive charge profile is crucial for endosomal escape and cytoplasmic release of siRNA or mRNA, distinguishing it from permanently charged lipids. However, Dlin-MC3-DMA is not universally optimal for every cell type, nucleic acid cargo, or administration route. For instance, delivery to non-hepatic tissues or across blood-brain barrier may require alternative LNP designs [6].

Common Pitfalls or Misconceptions

• Not all LNPs containing Dlin-MC3-DMA are optimized for extrahepatic delivery—tailored formulations may be needed for non-liver targets.
• Dlin-MC3-DMA is insoluble in water and DMSO; improper solvent use can result in precipitation and poor LNP formation.
• Storage above -20°C or prolonged solution exposure may lead to lipid degradation and loss of efficacy.
• Dlin-MC3-DMA is not a universal transfection reagent for DNA; it is optimized for siRNA and mRNA encapsulation.
• Assuming equivalence between Dlin-MC3-DMA and older ionizable lipids (e.g., DLin-DMA) ignores significant potency differences.

Workflow Integration & Parameters

Dlin-MC3-DMA is typically used in molar ratios of 50% (ionizable lipid), 10% (DSPC), 38.5% (cholesterol), and 1.5% (PEG-DMG) for LNP assembly. Ethanol stocks at ≥152.6 mg/mL are prepared for microfluidic or bulk mixing. The LNP/siRNA or LNP/mRNA complexes are dialyzed or buffer exchanged into PBS before in vivo use [3]. The A8791 kit from APExBIO provides research-grade Dlin-MC3-DMA for reproducible LNP preparation [2]. For troubleshooting and protocol optimization, see this detailed resource, which this article updates by including machine learning-driven design and in vivo benchmarks.

Conclusion & Outlook

Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) remains a reference standard for LNP-based siRNA delivery vehicles and mRNA drug delivery lipids. It is indispensable for hepatic gene silencing and has a proven track record in mRNA vaccine formulation. Ongoing research and predictive modeling are expanding its utility and guiding next-generation LNP design. For authoritative sourcing and product details, see APExBIO's product page. For molecular engineering perspectives, consult this analysis, which this article clarifies by providing updated evidence and experimental conditions.